The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models

The primary aim of this study was to evaluate the antitumor efficacy of the bromodomain inhibitor JQ1 in pancreatic ductal adenocarcinoma (PDAC) patient-derived xenograft (tumorgraft) models. A secondary aim of the study was to evaluate whether JQ1 decreases expression of the oncogene c-Myc in PDAC...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncogene 2016-02, Vol.35 (7), p.833-845
Hauptverfasser:	Garcia, P L, Miller, A L, Kreitzburg, K M, Council, L N, Gamblin, T L, Christein, J D, Heslin, M J, Arnoletti, J P, Richardson, J H, Chen, D, Hanna, C A, Cramer, S L, Yang, E S, Qi, J, Bradner, J E, Yoon, K J
Format:	Artikel
Sprache:	eng
Schlagworte:	13/1 13/51 14/63 45/77 631/67/1059/602 64/60 82/29 Adenocarcinoma Animals Antineoplastic Agents - pharmacology Antitumor activity Apoptosis Apoptosis - drug effects Azepines - pharmacology c-Myc protein Cancer Carcinoma, Pancreatic Ductal - pathology Cdc25B phosphatase Cell Biology Cell cycle Development and progression Gene expression Gene Expression - drug effects Genes, myc Genetic aspects Health aspects Human Genetics Humans Immunoblotting Immunohistochemistry Internal Medicine Medicine Medicine & Public Health Mice Mice, SCID Myc protein Nerve Tissue Proteins - antagonists & inhibitors Oligonucleotide Array Sequence Analysis Oncogenes Oncology original-article Pancreas Pancreatic cancer Pancreatic Neoplasms - pathology Patients Pharmaceutical sciences Polymerase Chain Reaction Protein expression Receptors, Cell Surface - antagonists & inhibitors Tissue inhibitor of metalloproteinase 3 Triazoles - pharmacology Tumors Xenograft Model Antitumor Assays Xenografts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!